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states were used for the purpose of this study. A retrospective matched cohort 
study design was used. Study sample included individuals who were continuously 
enrolled in the Medicaid managed care program from 2006 to 2008, were between 
18 to 65 years of age during the study period, had no previous history of cancer and 
had at least one inpatient and/or two outpatient claims for melanoma. Propensity 
scores were used to match melanoma patients with non-cancer controls (1:2 
ratio). Melanoma-related healthcare use was determined in terms of inpatient 
(IP), emergency room (ER) visits, outpatient (OT) visits. Drug and treatment use 
(surgery or radiation therapy) was also studied. Wilcoxon rank sum tests were 
used to compare all-cause resource use between melanoma cases and non-cancer 
controls. RESULTS: 14,750 incident cases of melanoma in 2007 were identified. 
In terms of age, gender, and region, most were white (63.91%), female (72.80%), 
and from the northeast (32.56%) region of the country. Mean melanoma-related 
OT visits were significantly lower for blacks (4.038) as compared to whites (4.383). 
Melanoma surgery (78.75%) was the most commonly used treatment followed by 
radiation therapy (63.01%). Mean all-cause IP (0.229 vs 0.215), ER (3.637 vs 1.545), 
and OT visits (87.272 vs 52.785) were significantly higher for melanoma cases as 
compared to non-cancer controls. CONCLUSIONS: The healthcare resource and 
treatment use for melanoma varied by demographic characteristics. Melanoma 
diagnosis was found to be associated with significant healthcare resource utili-
zation burden.
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OBJECTIVES: Value of information analysis provides an analytic framework to 
understand prioritization of future research, and is increasingly used for research 
planning. Our objective was to explore the need for future research on expanding 
current human papillomavirus (HPV) vaccination guideline to include men who 
have sex with men (MSM), 27 years or older, treated for high-grade anal intraepi-
thelial neoplasia (HGAIN). METHODS: We used two separate Markov models for 
HIV-positive and HIV-negative MSM to evaluate the inclusion of quadrivalent HPV 
(qHPV) vaccine as adjuvant/secondary prevention strategy in these subgroups. Using 
the healthcare payer’s perspective, the simulation over patients’ lifetimes was con-
ducted discounting costs and benefits. We estimated the population-level expected 
value of perfect information (pEVPI), and population-level expected value of partial 
perfect information (pEVPPI) for six key model parameters—HGAIN to anal cancer 
progression, HGAIN regression, HGAIN recurrences, HPV incidence, vaccine efficacy, 
and utilities (measure of preference-based quality of life)—over the period of 20 
years in the U.S. RESULTS: The pEVPI peaked in HIV-positive and HIV-negative MSM 
at the willingness-to-pay threshold (WTP) of $6,000/QALY (pEVPI was $7.3 million) 
and WTP of $75,000/QALY (pEVPI was $1.0 million), respectively. The pEVPI in HIV-
positive and HIV-negative MSM at the economically acceptable WTP of $50,000/QALY 
were $0 and $714,831, respectively. The two parameters with highest pEVPPI in HIV-
negative MSM at that WTP were vaccine efficacy (pEVPPI was $280,230) and HGAIN 
to anal cancer progression (pEVPPI was $10,807). CONCLUSIONS: In HIV-positive 
MSM, future research will be highly unlikely to change the cost-effectiveness of 
the vaccine; therefore implementation of the vaccination policy before the results 
of the ongoing clinical trials become available should be a priority. In HIV-negative 
MSM, a clinical trial is required before policy implementation. In both HIV-positive 
and HIV-negative MSM, further research is needed on estimation of HGAIN to anal 
cancer progression.
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OBJECTIVES: Adhering to prescribed medications is crucial for patients with chronic 
diseases to manage their conditions. However, rates of adherence to maintenance 
medications are often suboptimal, and forgetfulness is one of the most common 
reasons cited for nonadherence. Our objective is to evaluate the impact of an email 
refill reminder system on patient adherence to medications used to treat chronic 
conditions. METHODS: This retrospective cohort study used a propensity score 
matched (PSM) control group. Patients who received email refill reminders the first 
time in April 2013 comprised the test group. The control group included patients 
who did not receive the reminders and were propensity matched 1:1 to the test 
group based on baseline characteristics of age, gender, medications, patient fill 
status, baseline adherence rate, and therapeutic class. Medication adherence and 
persistence were calculated and compared between test and control groups in a 
12-month follow-up period. Medication adherence was evaluated using continu-
ous and categorical proportion of days covered (PDC) measures. Medication persis-
tence was measured using days on therapy (persistence) and percent of patients on 
therapy. RESULTS: After PSM, test and control group included 14,527 patients each 
and their baseline characteristics were comparable. One-year PDC for patients in 
the test group was 2.59% higher compared to the control group (51.15% vs. 48.56%, 
P < .001). Persistence for the test group was 7.90 days higher than in the control 
group (236.01 vs. 228.11, p< .001). At the one-year follow-up, 43.79% of patients in 
the test group stayed on their therapy compared to 40.99% in the control group 
(P< . 001). CONCLUSIONS: Patients receiving email refill reminders demonstrated 
better adherence and persistence to maintenance medications than patients who 
did not receive the reminders.
sensitivity analyses were performed for all key parameters across the three time 
horizons and different percentages of drug provision (5%, 10% and 15%). RESULTS: 
For 1190 patients, we expect health system costs of $75 million over a 10-year 
horizon and $120 and $142 million over 20 and 30 year horizons (2012 CAD$). We 
estimated 580 deaths over 30 years, of which 52% will be due to HCV. Antiviral treat-
ment will have been received by 1097 patients and 184 will have received a liver 
transplant. The sensitivity analysis shows that fibrosis stage at diagnosis will have 
the greatest impact on costs. Other key variables generating costs were liver-related 
morbidity and transplants. The need for transplants decreases when antiviral use 
increases. This offsets antiviral drug costs. CONCLUSIONS: Our model indicates that 
the amount of resources required by a single cohort of Albertans is substantial. The 
model also provides a resource which planners can use to estimate funding, as they 
will be responsible for allocating the resources needed to treat HCV.
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OBJECTIVES: This study estimated the healthcare resource use (HRU) associated 
with the treatment of metastatic melanoma (stages IIIB–IV) in Australia, Canada, 
France, Germany, Italy, the Netherlands, Spain, and the UK. METHODS: Using pub-
lished literature and clinician opinions, four treatment phases for metastatic mela-
noma were identified: active treatment (pre-progression), disease progression, best 
supportive care (BSC) or palliative care, and terminal care. The elements of HRU for 
each phase were identified. For most elements, estimates of the magnitude and 
frequency of use in clinical practice were not available from published literature and 
were obtained in 2014 through Delphi panels in each country, comprising up to eight 
experienced oncologists who treated patients with metastatic melanoma. RESULTS: 
Medical oncologists are the key care providers for patients with metastatic mela-
noma in all countries studied except Germany, where dermato-oncologists can also 
lead care. Each patient was estimated to require 1–2 consultations per month with 
a medical oncologist during active treatment phase. HRU during active treatment 
phase included an average of 1.16 physician consultations (range: 0.65–2.70), 1.23 
CT imaging scans (0.88–1.5), and 1.35 day-hospital visits (0–2.7) per 3 months across 
all countries. HRU was intensive during disease progression phase, including an 
average of 0.47 inpatient admissions and 1.23 radiotherapy fractions. The use of pal-
liative and hospice care during the BSC/palliative and terminal phases varied across 
countries. CONCLUSIONS: This study generated estimates of healthcare resource 
use in managing patients with metastatic melanoma using a consistent, robust 
methodology across eight countries. The estimates of magnitude and frequency of 
healthcare resource use were substantial and varied for some resources, particularly 
those used after disease progression.
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OBJECTIVES: This study assessed the association between forced vital capacity 
(FVC) change post-diagnosis of idiopathic pulmonary fibrosis (IPF) and healthcare 
resource utilization (HRU) in patients with newly diagnosed IPF. METHODS: A ret-
rospective chart review was conducted by US pulmonologists using an online case 
report form for patients diagnosed with IPF from 01/2011-06/2013. Patient eligibility 
criteria included: 1) ≥ 40 years old at IPF diagnosis; 2) IPF confirmed by lung biopsy 
and/or high-resolution computed tomography; 3) FVC results at diagnosis and ~6 
months following diagnosis. Based on relative change in FVC percent predicted 
(FVC%pred), patients were categorized as stable (decline< 5%), marginal decline 
(decline 5-9%), or significant decline (decline≥ 10%). Physician-reported IPF-related 
HRU included visits for urgent care or suspected acute exacerbation (AEx) and hos-
pitalization. All outcomes were assessed from six months post-diagnosis to end of 
observation. HRU rates by FVC decline group were estimated and compared using 
unadjusted negative binomial regression, controlling for varying follow-up peri-
ods. A multivariable Cox model was constructed to assess risk of hospitalization 
post-FVC decline. RESULTS: The sample included 490 IPF patients from 168 pul-
monologists with 250 (51%), 98 (20%), and 142 (29%) patients in the stable, marginal 
decline, and significant decline groups, respectively. At diagnosis, the mean age 
was 61±11 years, 68% were male, and the mean FVC%pred was 60±26%. The mean 
observation time across patients was 583±287 days. Groups with greater FVC decline 
exhibited higher rates of hospitalization and visits for urgent care or suspected 
AEx. Multivariable analysis showed that the significant (HR= 3.6 [95%CI: 2.0-6.6]) 
and marginal decline (HR= 2.4 [95%CI: 1.2-4.8]) groups were associated with higher 
risk of hospitalization than the stable group. CONCLUSIONS: Our findings suggest 
that greater FVC decline in the first six months post-diagnosis is associated with 
increased IPF-related HRU. Management options for IPF that slow FVC decline may 
help lessen future IPF-related HRU.
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OBJECTIVES: Melanoma is the most common kind of cancer in the United States. 
Low socio-economic status is associated with a diagnosis of melanoma at an 
advanced stage and higher mortality. The objectives of this study were to examine 
the healthcare resource utilization and treatment profile of adults with melanoma 
enrolled in Medicaid program. METHODS: The 2006-2008 Medicaid data for 36 
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OBJECTIVES: The aims of this study were (1) to determine the change in patients’ 
knowledge about their disease and treatment; (2) to assess the percent change in 
values of glycated hemoglobin (HbA1c) and change in blood pressure in mmHg; 
and (3) to evaluate adherence status, measured through pill counts. METHODS: A 
prospective study was conducted using patients with a diagnosis of both T2DM and 
hypertension at Arauco hospital in Arauco, Chile. Each patient participated in three 
interviews over a period of six months. The study incorporated a tailored pharmaco-
therapeutic intervention plan that included written and oral information regarding 
pathologies and pharmacological treatment. To determine treatment adherence, a 
pill count method was performed during each interview. Change in patient adher-
ence and knowledge of the diseases and treatments was assessed using the Fisher 
exact test. The difference in HbA1c and blood pressure between the initial and final 
sessions was evaluated using Student’s t-test. Analyses were performed using SPSS 
version 17. RESULTS: A total of 50 patients were selected, of whom 33 (66%) were 
female. At the beginning of the program, 30% of patients were found to be adherent. 
At the end of the study, this number had increased to 46% (p-value: 0.099). 10% of 
patients had full knowledge of their disease at baseline. At the end of the study, this 
number had increased to 66% (p-value < 0.001). After the completion of the inter-
views, significant decreases were observed for HbA1c (p-value < 0.001), and systolic 
blood pressure (p-value < 0.001). Stratified by sex, stronger and more significant 
decreases were observed for females in terms of both HbA1c (0.63%, p-value= 0.003) 
and systolic blood pressure (17 mmHg, p-value < 0.001). CONCLUSIONS: A pharma-
cotherapeutic optimization plan based on improved patient adherence and knowl-
edge and implemented for patients with chronic conditions, such as T2DM and 
hypertension, has had a positive impact on therapeutic outcomes.
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OBJECTIVES: The aim of the study is to develop and validate a decision aids (DA) fro 
Arabic depressed patients. METHODS: A six-page DA booklet published by Agency 
for Health Care Research and Quality (AHRQ) was adapted and translated to Arabic 
using Brisling’s back translation model. The work of Al-Muhtaseb was followed to 
produce a natural Arabic text. Validation was carried out by 24 experts (Physicians, 
Pharmacists, Academic staff and depressed Patients).International Patient Decision 
Aid Standards (IPDAS) Criteria Checklist was used to examine the DA structure 
and content. RESULTS: Experts strongly agree that the DA will increase patient’s 
recognition, knowledge and understanding of their condition and options, based 
on (IPDAS). 83% of experts report that DA provide information about options in 
sufficient detail for decision making, 68% present probabilities of outcomes is an 
unbiased and understandable way, 85% clarifying and expressing patients values 
and 87% for structure guidance in deliberation and communication with a total of 
81% for the whole content criteria. Secondly, the development process has 63% posi-
tive feedback. Particularly, 83% agreed that the information are present in balanced 
manner, 65% for having a systematic development process, 71% for using a scientific 
evidence data , 69% for using plain language but less than half of the experts agreed 
with the disclosing conflicts of interest. Finally, the sum of expected effectiveness 
criteria got a very high percentage (93%). In addition, experts provided constructive 
feedback with some modification regarding the language and general layout of the 
DA. CONCLUSIONS: Up to our knowledge we developed and validated the first 
Arabic DA based on IPDAS criteria for depressed patients. Future research needed 
to assess the effectiveness of this DA on depressed patient involvement in SDM.
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OBJECTIVES: The normal life of patients is seriously affected by Diabetes Mellitus 
(DM). According to Diabetes Atlas it is estimated that 61.3 million people live with 
diabetes in India (2011 estimates) and77.2 million pre-diabetics. The objective of this 
study was to evaluate the impact of clinical pharmacist intervention by counselling 
on medication adherence and quality of life of diabetic patients. METHODS: The 
study sample was extracted from a reputed diabetic clinic of Warangal, India over 
a period of six months. About 175 patients diagnosed with diabetes were recruited 
and were randomized into test (n= 85) and control (n= 90). Health Related Quality 
of Life of patients was assessed using 19 domain Audit of Diabetes Dependent 
Quality of Life (ADDQoL) questionnaires and medication adherence was assessed 
using Brief Medication Questionnaire (BMQ). BMQ and ADDQoL questionnaires 
were administered at baseline and subsequent four follow-ups each of one month 
duration. Test group patients administered with structured patient education by 
using various counselling aids on monthly basis and controlled group patients 
were deprived of the same. The data was subjected to relevant statistics. RESULTS: 
The study reveals that there is a highest impact of patient education on working 
life, physical activity, financial condition and their freedom to eat and drink fol-
lowed by other quality of life domains in diabetic patients. The mean fasting blood 
sugar and post prandial blood sugar values of each phase were correlated and was 
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OBJECTIVES: To compare the medication adherence and persistence of existing 
users of chronic medications enrolled in a pharmacy chain’s appointment-based 
medication synchronization (ABMS) program, with patients who are not enrolled in 
the program for the duration of one year. METHODS: A retrospective cohort study 
compared patients receiving ABMS with matched controls receiving usual standard 
care. ABMS consisted of an appointment to synchronize the patient’s medications to 
be dispensed on a single appointment day every month, a call to the patient prior to 
the appointment day to address any prescription changes and to remind the patient, 
and a patient visit to the pharmacy to pick up the medication. Outcomes meas-
ured were 1-year adherence rates using proportion of days covered (PDC) and 1-year 
non-persistence rates. Data for this study came from prescription claims records of 
patients taking one of six chronic medication classes during the period of December 
1, 2011 to February 28, 2014. ABMS patients were matched with controls on prior 
adherence behavior, medication class, age, gender, and geographic region. RESULTS: 
Mean PDC scores ranged from 0.73 to 0.91 for ABMS patients, and from 0.57 to 0.71 for 
controls depending on the medication class. The percentage of adherent individuals 
(i.e., PDC≥ 0.8) was 55% to 84% for ABMS participants and 37% to 62% for controls. Odds 
of adherence was 2.3 to 3.6 times greater with ABMS. Controls became non-persistent 
(61% to 74%) more often than ABMS patients (33% to 44%) with hazard ratios of non-
persistence being 0.39 to 0.67 for individuals in the program. Compared to controls, 
study patients had a 33% to 61% lower likelihood of non-persistence, depending on 
the drug class. CONCLUSIONS: ABMS program in a community pharmacy setting was 
associated with significant improvements in adherence and persistence for patients 
who were existing users of chronic medications for at least six months.
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OBJECTIVES: To examine the difference in the adherence of patients with metabolic 
syndrome receiving a hybrid model of care compared to other community phar-
macy models. METHODS: Prospective, randomized-control trial design conducted 
through an integrated delivery network in Northwest Ohio. Patients required to 
have Paramount health insurance, type 2 diabetes, hypertension, hyperlipidemia, 
prescribed at least five oral medications, and prescribed an oral medication for each 
disease state. Patients randomly assigned to one of four groups. The first group 
received standard pill bottles. The second group received adherence packaging and 
refill synchronization. The third group received pill bottles and medication therapy 
management (MTM) using an appointment-based model. The fourth group received 
the hybrid model, including adherence packaging, refill synchronization, and MTM 
using the appointment-based model. Adherence was measured using patient-
reported pill count. RESULTS: The sample (n= 26) was predominantly female, aver-
age age 61 years. Types of insurance included Medicaid(7.14%), Medicare(28.57%), 
and commercial insurance(64.29%). Adherence ranged from 29% to 100% among all 
participants. Interim, three-month results showed that the greatest improvement in 
medication adherence over time was seen in the hybrid model group, from 23.6% to 
81.6%. CONCLUSIONS: These preliminary results show that the hybrid model group 
has the potential to positively impact medication adherence. This is an ongoing 
study. Further results are needed to fully analyze the benefit of the hybrid pharmacy 
practice model of care.
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OBJECTIVES: Adherence to antiretroviral therapy (ART) is a main concern in the 
control of HIV and is associated with treatment success or failure. The aim of this 
study was to determine adherence to ART using three methods and to identify fac-
tors related with non-adherence. METHODS: The study included 225 HIV patients 
under treatment at Regional Hospital in Concepción, Chile. Adherence was meas-
ured through two indirect methods: (1) the simplified medication adherence ques-
tionnaire (SMAQ), a survey including four questions with dichotomous answers, one 
question with a categorical answer, and one question with an open answer; and (2) 
a pharmacy dispensation register (PDR), which measures adherence through a ratio 
defined as number of days for which the supply of medication dispensed was pre-
scribed divided by days between prescription fills; and through one direct method: 
(3) measuring viral load and CD4+ cell count. These methods were compared and a 
global weighted adherence measure was calculated for the 47 patients that received 
all three evaluations. RESULTS: According to the SMAQ, 51% of patients were adher-
ent; while 43% were adherent according to PDR, and 50% were adherent according 
to the direct method. Weighted adherence was 21%. Main causes of non-adherence 
were: delay in medication refill (43%); lack of information regarding ART (43%); 
forgetting doses (36%); and adverse reaction (35%). Patients were more adherent to 
treatment with the combination of two nucleoside reverse transcriptase inhibitors 
and one non-nucleoside reverse transcriptase inhibitor (33%) than with the same 
combination plus protease inhibitor (12%). CONCLUSIONS: Adherence to HIV treat-
ment was below the Chilean average. Because the global weighted average was 
significantly less than the individual adherence percentages, each method alone 
is not sufficient to obtain a reliable determination of adherence. An evaluation of 
the impact of non-adherence behavior on the Chilean national HIV program is 
recommended.
